PPM-006 - Tailoring cancer treatment: How virtual trials and advanced modelling improves imatinib dosing for obese patients

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: PPM-006
• By: BADHAN, Raj (Aston University, United Kingdom)
• Co-author(s): Dr Raj Badhan (Aston University, Birmingham, United Kingdom)
  Dr Khairulanwar Burhanuddin (Ministry of Health , Malaysia)
  
• Abstract:

  Obesity is a major global health issue that significantly affects how drugs are processed in the body, impacting their effectiveness and safety. Imatinib, a tyrosine kinase inhibitor, is widely used to treat cancers such as chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GIST). However, standard dosing may not be optimal for..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login